Ads
related to: apalutamide for prostate cancer- Cancer Progression
Understand The Different Kinds Of
Prostate Cancer & Its Progression.
- Prostate Cancer Symptoms
Find Tips And Resources To Manage
Advanced Prostate Cancer.
- Support Your Loved Ones
Explore Resources And Get Guidance
On How To Care For Someone With PC.
- Patient Story Videos
Watch Real Stories Of Patients
Who Have Battled Prostate Cancer.
- Cancer Progression
Search results
Results from the WOW.Com Content Network
Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. [8] [9] [10] [15] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer. [2] [10] [9]
A 2015 Cochrane review found that NSAA monotherapy for prostate cancer had a greater risk of treatment discontinuation due to adverse effects than monotherapy with a GnRH agonist or surgical castration (RR = 1.82). [122] This included a greatly increased risk of breast pain (RR = 22.97) and gynecomastia (RR = 8.43). [122]
N-Desmethylapalutamide is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of apalutamide, an NSAA which is used as a hormonal antineoplastic agent in the treatment of metastatic prostate cancer.
Apalutamide (Erleada): Marketed for the treatment of prostate cancer. Very similar to enzalutamide, but with reduced central nervous system distribution and hence is expected to have a reduced risk of seizures and other central side effects. Enzalutamide (Xtandi): Marketed for the treatment of
2018: Apalutamide is first introduced for medical use, to treat prostate cancer [245] 2018: Elagolix is the first orally active GnRH antagonist to be introduced for medical use [ 217 ] 2019: Relugolix is the second orally active GnRH antagonist to be introduced for medical use [ 246 ]
The American Association for Cancer Research (AACR) even believes that alcohol should come with cancer warning labels—in fact, the U.S. Surgeon General recently issued an advisory on the causal ...
Ads
related to: apalutamide for prostate cancer